RESEARCH ARTICLE
Formulation and In-Vitro Evaluation of Solid Lipid Nanoparticles Containing Levosulpiride
Sukhwinder Singh, Sukhmeet Singh Kamal, Amit Sharma, Daljit Kaur, Manoj Kumar Katual, Rajesh Kumar*
Article Information
Identifiers and Pagination:
Year: 2017Volume: 4
First Page: 17
Last Page: 29
Publisher Id: TONMJ-4-17
DOI: 10.2174/1875933501704010017
Article History:
Received Date: 24/06/2017Revision Received Date: 10/09/2017
Acceptance Date: 25/09/2017
Electronic publication date: 31/10/2017
Collection year: 2017
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Objectives:
The present study aims on preparing Levosulpiride loaded solid lipid nanoparticles (SLNs) to reduce the dose, frequency of dosing, reduce side effects and to increase the bioavailable fraction of drug (<30% orally in general).
Methods:
Levosulpiride was characterized by preformulation studies like physical appearance, melting point, assay, calibration curve, FTIR analysis and DSC analysis. The calibration curve of the drug was prepared in pH 6.8 phosphate buffer. Two lipids (Stearic acid and Palmitic acid) were used as lipid phase to prepare SLNs. Factorial design (23) was applied to formulate 16 formulations (8 for each lipid i.e. SF1-SF8 and PF1-PF8). Levosulpiride SLNs were prepared by solvent evaporation method followed by homogenization.
Results:
The optimized formulations were characterized by particle size analysis, zeta potential analysis, in vitro drug release and drug release kinetics. Drug-excipient interaction in optimized formulation was characterized by FTIR, DSC and TEM analysis.
Conclusion:
On the basis of evaluation parameters, the formulation SF1 (containing Stearic acid) and PF1 (containing Palimitic acid) found to be better formulations amongst their groups with a controlled drug release after a period of 24 hrs.
